Truist raises Gilead Sciences price target to $158
Truist Securities raised its price target on Gilead Sciences to $158 from $150, per Benzinga’s ratings-action roundup.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.